Vol. 49 | No. 2 | July-December 2021Back

Open Access

Prevalence, Awareness, and Treatment Profile of Adult Filipino Hypertensive Individuals: Philippine Heart Association–Council on Hypertension Report on Survey of Hypertension (PRESYON-4)

Jorge A. Sison, Roberta Maria Cawed-Mende, Raymond V. Oliva
Dec 2021 DOI 10.69944/pjc.e0ed50316d

More Info

Jorge A. Sison, MD1 | Roberta Maria Cawed-Mende, MD2 | Raymond V. Oliva, MD3

 

1Consultant, Medical Center Manila, United Nations Ave, Manila 

2Chair, Council on Hypertension, Philippine Heart Association 

3Clinical Associate Professor, Division of Hypertension, Department of Medicine, Philippine General Hospital,  Taft Avenue, Manila

References
  1. Bina JJ, Noublap JJ. The rising burden of non communicable diseases in sub-Saharan Africa. Lancet Glob Health 2019;7(10e):1295–1296.
  2. Masilela C, Pearce B, Ongole JJ, Adeniyi OV, Mongi Benjeddou M. Cross-sectional study of prevalence and determinants of uncontrolled hypertension among South African adult residents of Mkhondo municipality. BMC Public Health 2022;20:1069.
  3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217–223.
  4. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;376:391–603.
  5. Dahlof B. Prevention of stroke in patients with hypertension. Am J Cardiol 2007;100:17J–24J.
  6. Gao Y, Chen G, Tian H, et al. Prevalence of hypertension in China: A cross-sectional study. PLoS One 2013;8(6):e65938.
  7. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation 2016;134:441–450.
  8. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959–968.
  9. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA. Guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2018;138:e484–e594.
  10. Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the association of the 2017 and 2015 hypertension guidelines with cardiovascular events and deaths in US adults: An analysis of nation data. JAMA Cardiol 2017;2:775–781.
  11. Wang Zm Chen Z, Zhang L, et al. Status of hypertension in China. Circulation 2018;137:2344–2356.
  12. 2013 8th National Nutrition Survey of the Food and Nutrition Research Institute, Department of Science and Technology. https://drive.google.com/file/d/1D6tbN4poyg3 WkAFRBboO3L16o2bd__W_/view
  13. Philippine Heart Association-Council on Hypertension. Philippine Heart Association—Council of Hypertension Report on Survey of Hypertension (PRESYON 3): A profile on prevalence of hypertension, awareness and treatment profile. Phil J Cardiol 2013;41(1):43–48.
  14. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines in the management of arterial hypertension. Eur Heart J 2018;00:1–98.
  15. Mills K, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol 2020;16(4):223–237. 16. Ostroff J, Wolff M. An overview of generic angiotensin receptor blockers. US Pharm 2016;41(6)(generic suppl):44–50.
  16. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352–358.
  17. Chalmers J, Mourad JJ, De Champvallins M, Mancia G. Benefits of indapamide-based treatment on mortality: A systematic review and meta-analysis. J Hypertens 2009;37:p357.
  18. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol and doxazosin to determine the treatment for drug-resistant hypertension (PATHWAY-2): A randomized, double-blind, crossover trial. Lancet 2015;386:2069.
  19. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther 2001;15:79–87.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.